Metagenomi Therapeutics Gross Margin 2022-2026 | MGX
Current and historical gross margin for Metagenomi Therapeutics (MGX) over the last 10 years. The current gross profit margin for Metagenomi Therapeutics as of June 30, 2026 is %.
| Metagenomi Therapeutics Gross Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM Gross Profit | Gross Margin |
| 2026-06-30 | $0.01B | $0.01B | 100.00% |
| 2026-03-31 | $0.02B | $0.02B | 100.00% |
| 2025-12-31 | $0.03B | $0.03B | 100.00% |
| 2025-09-30 | $0.03B | $0.03B | 100.00% |
| 2025-06-30 | $0.04B | $0.04B | 100.00% |
| 2025-03-31 | $0.05B | $0.05B | 100.00% |
| 2024-12-31 | $0.05B | $0.05B | 100.00% |
| 2024-09-30 | $0.06B | $0.06B | 100.00% |
| 2024-06-30 | $0.06B | $0.06B | 100.00% |
| 2024-03-31 | $0.05B | $0.05B | 100.00% |
| 2023-12-31 | $0.04B | $0.04B | 100.00% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.043B | $0.025B |
| Metagenomi Therapeutics Inc. is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. Metagenomi Therapeutics Inc., formerly known as Metagenomi Inc., is based in EMERYVILLE, Calif. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $44.899B | 17.67 |
| BridgeBio Pharma (BBIO) | United States | $13.352B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $9.749B | 24.85 |
| Aspen Pharmacare (APNHY) | South Africa | $4.248B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.409B | 20.18 |
| Bausch Health Cos (BHC) | Canada | $2.129B | 1.33 |
| Personalis (PSNL) | United States | $1.687B | 0.00 |
| Taysha Gene Therapies (TSHA) | United States | $1.652B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.019B | 9.58 |
| Assembly Biosciences (ASMB) | United States | $0.519B | 24.98 |
| Sol-Gel Technologies (SLGL) | Israel | $0.178B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |